Mira Katan1, Yeseon Moon2, Arnold von Eckardstein2, Kathartina Spanaus2, Janet DeRosa2, Jose Gutierrez2, Charles DeCarli2, Clinton Wright2, Ralph Sacco2, Mitchell Elkind2. 1. From the Departments of Neurology (M.K., Y.M., J.D.R., J.G., M.E.) and Epidemiology (M.E.), Columbia University, New York, NY; Departments of Neurology (M.K.) and Clinical Chemistry (A.v.E., K.S.), University Hospital of Zurich, Switzerland; Department of Neurology, University of California at Davis, Sacramento (C.D.C.); and Departments of Neurology (C.W., R.S.), Public Health Sciences (R.S.), and Human Genetics (R.S.), University of Miami, FL. mira.katan@usz.ch. 2. From the Departments of Neurology (M.K., Y.M., J.D.R., J.G., M.E.) and Epidemiology (M.E.), Columbia University, New York, NY; Departments of Neurology (M.K.) and Clinical Chemistry (A.v.E., K.S.), University Hospital of Zurich, Switzerland; Department of Neurology, University of California at Davis, Sacramento (C.D.C.); and Departments of Neurology (C.W., R.S.), Public Health Sciences (R.S.), and Human Genetics (R.S.), University of Miami, FL.
Abstract
BACKGROUND AND PURPOSE: Chronic infections and cardiac dysfunction are risk factors for stroke. We hypothesized that blood biomarkers of infection (procalcitonin) and cardiac dysfunction (midregional proatrial natriuretic peptide [MR-proANP]), previously associated with small vessel stroke and cardioembolic stroke are also associated with subclinical cerebrovascular damage, including silent brain infarcts and white matter hyperintensity volume. METHODS: The NOMAS (Northern Manhattan Study) was designed to assess risk factors for incident vascular disease in a multiethnic cohort. A subsample underwent brain magnetic resonance imaging and had blood samples available for biomarker measurement (n=1178). We used logistic regression models to estimate the odds ratios and 95% confidence intervals (95% CIs) for the association of these biomarkers with silent brain infarcts after adjusting for demographic, behavioral, and medical risk factors. We used linear regression to assess associations with log-white matter hyperintensity volume. RESULTS: Mean age was 70±9 years; 60% were women, 66% Hispanic, 17% black, and 15% were white. After adjusting for risk factors, subjects with procalcitonin or MR-proANP in the top quartile, compared with the lowest quartile were more likely to have silent brain infarcts (adjusted odds ratio for procalcitonin, 2.2; 95% CI, 1.3-3.7 and for MR-proANP, 3.3; 95% CI, 1.7-6.3) and increased white matter hyperintensity volume (adjusted mean change in log-white matter hyperintensity volume for procalcitonin, 0.29; 95% CI, 0.13-0.44 and for MR-proANP, 0.18; 95% CI, 0.004-0.36). CONCLUSIONS: Higher concentrations of procalcitonin, a marker of infection, and MR-proANP, a marker of cardiac dysfunction, are independently associated with subclinical cerebrovascular damage. If further studies demonstrate an incremental value for risk stratification, biomarker-guided primary prevention studies may lead to new approaches to prevent cerebrovascular disease.
BACKGROUND AND PURPOSE:Chronic infections and cardiac dysfunction are risk factors for stroke. We hypothesized that blood biomarkers of infection (procalcitonin) and cardiac dysfunction (midregional proatrial natriuretic peptide [MR-proANP]), previously associated with small vessel stroke and cardioembolic stroke are also associated with subclinical cerebrovascular damage, including silent brain infarcts and white matter hyperintensity volume. METHODS: The NOMAS (Northern Manhattan Study) was designed to assess risk factors for incident vascular disease in a multiethnic cohort. A subsample underwent brain magnetic resonance imaging and had blood samples available for biomarker measurement (n=1178). We used logistic regression models to estimate the odds ratios and 95% confidence intervals (95% CIs) for the association of these biomarkers with silent brain infarcts after adjusting for demographic, behavioral, and medical risk factors. We used linear regression to assess associations with log-white matter hyperintensity volume. RESULTS: Mean age was 70±9 years; 60% were women, 66% Hispanic, 17% black, and 15% were white. After adjusting for risk factors, subjects with procalcitonin or MR-proANP in the top quartile, compared with the lowest quartile were more likely to have silent brain infarcts (adjusted odds ratio for procalcitonin, 2.2; 95% CI, 1.3-3.7 and for MR-proANP, 3.3; 95% CI, 1.7-6.3) and increased white matter hyperintensity volume (adjusted mean change in log-white matter hyperintensity volume for procalcitonin, 0.29; 95% CI, 0.13-0.44 and for MR-proANP, 0.18; 95% CI, 0.004-0.36). CONCLUSIONS: Higher concentrations of procalcitonin, a marker of infection, and MR-proANP, a marker of cardiac dysfunction, are independently associated with subclinical cerebrovascular damage. If further studies demonstrate an incremental value for risk stratification, biomarker-guided primary prevention studies may lead to new approaches to prevent cerebrovascular disease.
Authors: Joachim Struck; Martina Strebelow; Sonja Tietz; Christine Alonso; Nils G Morgenthaler; Johannes G van der Hoeven; Peter Pickkers; Andreas Bergmann Journal: Clin Chem Date: 2009-07-02 Impact factor: 8.327
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Marius de Groot; Benjamin F J Verhaaren; Renske de Boer; Stefan Klein; Albert Hofman; Aad van der Lugt; M Arfan Ikram; Wiro J Niessen; Meike W Vernooij Journal: Stroke Date: 2013-02-21 Impact factor: 7.914
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Clinton B Wright; Myunghee C Paik; Truman R Brown; Sally P Stabler; Robert H Allen; Ralph L Sacco; Charles DeCarli Journal: Stroke Date: 2005-05-05 Impact factor: 7.914
Authors: C DeCarli; D G Murphy; M Tranh; C L Grady; J V Haxby; J A Gillette; J A Salerno; A Gonzales-Aviles; B Horwitz; S I Rapoport Journal: Neurology Date: 1995-11 Impact factor: 9.910
Authors: Razvan T Dadu; Myriam Fornage; Salim S Virani; Vijay Nambi; Ron C Hoogeveen; Eric Boerwinkle; Alvaro Alonso; Rebecca F Gottesman; Thomas H Mosley; Christie M Ballantyne Journal: Stroke Date: 2013-05-09 Impact factor: 7.914
Authors: Patrick M Meyer Sauteur; Selina Krautter; Lilliam Ambroggio; Michelle Seiler; Paolo Paioni; Christa Relly; Riccarda Capaul; Christian Kellenberger; Thorsten Haas; Claudine Gysin; Lucas M Bachmann; Annemarie M C van Rossum; Christoph Berger Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079